Investigation Overview
November 11, 2013 (Shareholders Foundation) - An investigation on behalf of investors, who currently hold shares of Santarus, Inc. (NASDAQ:SNTS) shares, was announced concerning whether the takeover of Santarus, Inc. by Salix Pharmaceuticals, Ltd for $32.00 per share is unfair to NASDAQ:SNTS stockholders. The investigation by a law firm concerns whether certain officers and directors...
You must register (for free) or login to view the entire investigation.